Ziling Liu
Impact in
Papers in
- Oncology 17
- Cancer Immunotherapy and Biomarkers 7
- Lung Cancer Research Studies 5
- PARP inhibition in cancer therapy 4
-
- Ovarian cancer diagnosis and treatment 6
- Co-authors
- Rui Guo (2 shared papers)Hong Wang (2 shared papers)Shuai Qian (1 shared paper)Jianjun Zhang (1 shared paper)Yuan Gao (1 shared paper)Jing Gao (1 shared paper)Wei Li (1 shared paper)Hua He (2 shared papers)
- Journals
- Frontiers in Oncology (4 papers)Frontiers in Immunology (4 papers)Medicine (4 papers)Gynecologic Oncology (3 papers)The Oncologist (2 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Ziling Liu
46 papers receiving 949 citations
Ziling Liu's Hit Papers
Peers
Comparison fields: 5 of 72
- Genetics 100
- Oncology 243
- Reproductive Medicine 76
- Cancer Research 82
- Hepatology 47
Countries citing papers authored by Ziling Liu
This map shows the geographic impact of Ziling Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziling Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziling Liu more than expected).
Fields of papers citing papers by Ziling Liu
This network shows the impact of papers produced by Ziling Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziling Liu. The network helps show where Ziling Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ziling Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immunotherapy: a promising approach for glioma treatment Hit paper breakdown → | 2023 | 153 |
| 2 | Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials Hit paper breakdown → | 2023 | 122 |
| 3 | 2023 | 115 | |
| 4 | 2012 | 74 | |
| 5 | 2022 | 66 | |
| 6 | 2021 | 57 | |
| 7 | 2015 | 43 | |
| 8 | 2019 | 31 | |
| 9 | 2019 | 29 | |
| 10 | 2019 | 25 | |
| 11 | 2015 | 23 | |
| 12 | 2021 | 22 | |
| 13 | 2022 | 17 | |
| 14 | 2023 | 17 | |
| 15 | 2024 | 16 | |
| 16 | 2003 | 15 | |
| 17 | 2015 | 14 | |
| 18 | 2022 | 14 | |
| 19 | 2019 | 13 | |
| 20 | 2021 | 13 |
About Ziling Liu
Ziling Liu is a scholar working on Oncology, Reproductive Medicine, Pulmonary and Respiratory Medicine, Hematology and Hepatology, having authored 50 papers that have together received 980 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Ovarian cancer diagnosis and treatment (6 papers), Lung Cancer Research Studies (5 papers), PARP inhibition in cancer therapy (4 papers), Bladder and Urothelial Cancer Treatments (3 papers), Lung Cancer Treatments and Mutations (2 papers), Renal cell carcinoma treatment (2 papers) and Acute Myeloid Leukemia Research (2 papers). The work is most often cited by research in Genetics (100 citations), Oncology (243 citations), Reproductive Medicine (76 citations), Cancer Research (82 citations) and Hepatology (47 citations). Ziling Liu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Rui Guo, Hong Wang, Shuai Qian, Jianjun Zhang, Yuan Gao, Jing Gao, Wei Li, Hua He, Xu Wang and Ji‐Fan Hu. Their work appears in journals such as Frontiers in Oncology, Frontiers in Immunology, Medicine, Gynecologic Oncology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.